TIRZ
TIRZ (Dual Incretin Receptor Agonist)
At a Glance
Molecular Properties
Overview
Compound Description
TIRZ is a synthetic 39-amino-acid peptide designed as a dual agonist that selectively binds and activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and a second complementary incretin receptor. The molecule incorporates two alpha-aminoisobutyric acid (Aib) residues at positions 2 and 13 for protease resistance, a C-terminal amide, and a C20 fatty diacid moiety conjugated at Lys20 that enables albumin binding and extends half-life. It is supplied as a characterized reference compound for in-vitro receptor-pharmacology and analytical method development, and is not for human or animal use.
Mechanism of Action
Research-Identified Pathways
TIRZ simultaneously engages two incretin receptors that play complementary roles in metabolic regulation. GIP receptor activation on pancreatic beta cells potentiates glucose-dependent insulin secretion, while agonism at the second incretin receptor reduces glucagon secretion and slows gastric emptying. Receptor-pharmacology studies compare the signaling profile of dual engagement against single-receptor agonists at the level of cAMP accumulation and beta-arrestin recruitment in cell-based assays.
The GIP receptor component is also expressed on adipocytes, where cell-culture studies report effects on lipid handling and lipolytic signaling. The C20 fatty diacid modification enables non-covalent albumin binding, resulting in a half-life of approximately 5 days that supports once-weekly administration.
Key Research Findings
Published Study Highlights
- Engineered as a dual agonist engaging both the GIP receptor and a second incretin receptor, each a class B G-protein-coupled receptor
- Two alpha-aminoisobutyric acid residues at positions 2 and 13 are studied as substitutions conferring resistance to proteolytic degradation
- A C20 fatty diacid conjugated at Lys20 enables albumin binding, extending circulating half-life in published pharmacokinetic models
- Investigated in receptor-pharmacology work for biased signaling at the incretin receptor relative to single-receptor agonists
- Used as an analytical reference standard in LC-MS and HPLC characterization of multi-agonist peptides
Areas of Research Interest
Why Researchers Are Investigating This Compound
This compound has attracted significant research attention in the following areas. These represent active fields of scientific inquiry, not validated therapeutic claims. No medical benefits are stated or implied.
- Dual-receptor pharmacology: a reference compound for laboratory studies of simultaneous agonism at two class B GPCRs
- Biased agonism research: investigated for differential G-protein versus beta-arrestin recruitment at the incretin receptor
- Peptide engineering: the Aib substitutions and C20 diacid linker are studied as protease-resistance and half-life-extension strategies
- Analytical method development: employed as a characterized standard in LC-MS/MS assay validation
Research Use Only
The information presented on this page is compiled from peer-reviewed scientific literature and is provided solely for educational and research purposes. This compound is intended exclusively for laboratory and scientific research use. It is not a drug, pharmaceutical, or dietary supplement. It is not intended to diagnose, treat, cure, or prevent any disease or medical condition. No claims of therapeutic efficacy are made or implied.
Researchers are advised to consult the original published studies referenced above for complete methodological details, study limitations, and the authors' own conclusions. Atlas Peptide Research does not endorse any specific research application and provides this information as a reference resource only.
Interested in TIRZ?
View this compound in our shop to see available sizes, certificates of analysis, and current pricing.
View in Shop